NL-OMON46824已完成不适用
The clinical evaluation of the effectiveness of two oral probiotic strains on gingival health. - The PrOH-ACT study
Academisch Centrum Tandheelkunde Amsterdam (ACTA)0 个研究点目标入组 117 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 117
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Willing and able to give written informed consent and willing and able to comply to all study procedures; Adult, * 18 years - 55 years; Systemically healthy, as assessed by a medical questionnaire (no systemic diseases); Minimum of 20 natural teeth: at least the first or second molar must be present in each quadrant; Having visited the dentist for a regular check-up within the last year and having finished the necessary treatment(s);
排除标准
- •ACTA dental student or ACTA employee; Participation in a clinical study within the previous 30 days; Allergy/Intolerance to the test and placebo products (ingredients) in particular lactose and milk protein content (allergens) in the test products; not having a good general health and/or oral health.
研究者
相似试验
已完成
不适用
De beoordeling van de effectiviteit van twee probiotica bij het in stand houden van de mondgezondheid: een praktijkonderzoek.NL-OMON25529Ir. W. Th. FokkemaACTA Dental Research B.V. (ADR)Gustav Mahlerlaan 30041081 LA Amsterdam, NLw.fokkema@acta.nl / +31 6 28 724 788117
已完成
不适用
A Clinical Study to evaluate the effect of two different combinations of BP medication in patients with uncontrolled BPCTRI/2018/08/015555Current Medical Concepts Pvt Ltd93
招募中
3 期
Comparison of the clinical effectiveness of the two different doses of Meropenem in pneumoniaIRCT20100107003014N19Sari University of Medical Sciences62
进行中（未招募）
1 期
A clincial study comparing the effectiveness of two doses of the drug Rituximab during long-term treatment of the neurological disease Multiple Sclerosis.EUCTR2018-000721-31-SEDepartment of Clinical Sciences, Karolinska Institutet Danderyd Hospital200
进行中（未招募）
1 期
A clincial study comparing the effectiveness of two drugs, named Rituximab and Dimethyl Fumarate (Tecfidera®), for the neurological disease Multiple Sclerosis.Patients with multiple sclerosis (MS) or patients presenting with symptoms highly suspicious of MS while not completely fulfilling diagnostic criteria, 18 - 50 years of age and no more than 10 years of disease duration (from diagnosis). Patients treated with immunomodulatory drugs or treated with first-line injectable therapies (eg interferons or glatiramer acetate) may be included.EUCTR2015-004116-38-SEDepartment of Clinical Sciences, Danderyd Hospital200